@article{c0b4f27c8eb94474b2a9502e1d235d50,
title = "An evaluation of RAS testing among metastatic colorectal cancer patients in the USA",
abstract = "Background: Data on RAS testing practices prior to metastatic colorectal cancer (mCRC) treatment initiation are lacking in the USA. Materials & methods: Flatiron data were utilized for patients diagnosed with mCRC between 2011 and 2017. Flatiron is a longitudinal, demographically and geographically diverse database representing data from over 1.5 million active US patients treated at 255 community and hospital-affiliated oncology clinics. Results: Among 17,387 mCRC patients 69% were RAS tested and 31% were never tested. Timing of RAS testing was as follows: 23% were tested at the time of their initial CRC diagnosis, 60% following mCRC diagnosis but prior to first line of treatment, 3% prior to third line, the remaining 14% were tested following third line. Conclusion: A third (31%) of patients failed to receive RAS testing, therefore all treatment options were unavailable to them. These data highlight how universal testing has not been achieved.",
keywords = "RAS, anti-EGFR, metastatic colorectal cancer, panitumumab",
author = "Laura Sangare and Kimberly Delli-Zotti and Ana Florea and Marko Rehn and Benson, {Al B.} and Lowe, {Kimberly A.}",
note = "Funding Information: This research project was funded by Amgen, Inc. Amgen was also involved in the study design, data collection and analysis, decision to publish and preparation of the manuscript. They also provided funding for journal publication fees. L Sangar{\'e} is an employee of SimulStat, work contracted through Amgen, Inc. K Delli-Zotti is a compensated employee of Amgen, Inc. and a stockholder of Amgen, Inc. A Florea was an intern at Amgen at the time this research was conducted. AB Benson is a consultant to Amgen and part of the Amgen Data Monitoring Committee at American Society of Clinical Oncology. M Rehn is a compensated employee of Amgen, Inc. and a stockholder of Amgen, Inc. KA Lowe is a compensated employee of Amgen, Inc. and a stockholder of Amgen, Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2021 Future Medicine Ltd.. All rights reserved.",
year = "2021",
month = may,
doi = "10.2217/fon-2020-1075",
language = "English (US)",
volume = "17",
pages = "1653--1663",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "13",
}
